Miroslav Dinic is a microbiologist whose research focuses on probiotics and microbiome science. He earned his PhD in Medical Sciences, specializing in Pharmaceutical Microbiology, from the Faculty of Pharmacy at the University of Belgrade.

His multidisciplinary research spans probiotic and microbiome science, with a primary focus on the microbiota-gut-brain axis and the role of gut microbiome in aging and aging-related neurodegenerative diseases. By integrating in vitro systems, in vivo models such as Caenorhabditis elegans, and translational approaches, his work aims to identify novel microbiota-based biomarkers associated with healthy aging and neuroprotective therapeutics. He is developing a microbial metabolite screening pipeline that integrates a transgenic C. elegans model with in vitro modeling of the human blood-brain barrier and ‘omics technologies to identify new drug candidates for treating neurodegenerative diseases.

As a recipient of Fulbright and FEMS fellowships, he received extensive postdoctoral research training in the University of Miami, USA and CECAD Research Center, University of Cologne, Germany, specializing in host-microbe interactions and the use of Caenorhabditis elegans as a model organism. He coordinated a work package within a national IDEAS research project focused on the selection of gut anaerobic bacteria with neuromodulatory effects. He also served as the principal investigator of the 'Start Up for Science' project, where he investigated microbial-derived molecules with the potential to slow down aging.